WallStSmart
NBY

NovaBay Pharmaceuticals Inc

NYSE MKT: NBY · HEALTHCARE · BIOTECHNOLOGY

$1.95
+22.64% today

Updated 2026-04-02

Market cap
$51.92M
P/E ratio
P/S ratio
0.16x
EPS (TTM)
$-28.50
Dividend yield
52W range
$1 – $100
Volume
1.3M

NovaBay Pharmaceuticals Inc (NBY) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
1 of 8
Last 8 quarters
Avg EPS surprise
-64.9%
Last 4 quarters
Revenue YoY growth
-78.7%
Most recent quarter
EPS YoY growth
+61.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+0.9%
Last 1 reports
Positive reaction rate
100%
1 of 1 quarters
Largest single-day move
+0.9%
2025-11-07
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2025-11-07$-0.23-2200.0%$1.07$1.08+0.9%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-09-30$-0.01$-0.23-2200.0%$521000.00-78.7%
2025-06-30$-0.21$-0.34-61.9%
2025-03-31$-0.24$-0.40-66.7%$2.31M-12.2%
2024-12-31$-1.20$-1.99-66.2%$2.31M-38.0%
2024-09-30$-0.30$-0.59-96.7%$2.44M-25.0%
2024-06-30$-1.23$-1.37-11.4%$2.40M-32.1%
2024-03-31$-0.15$-0.15+0.0%$2.63M+12.5%
2023-12-31$-0.30$-1.33-343.3%$3.73M
2023-09-30$-0.40$-0.37+7.5%$3.25M
2023-06-30$-0.56$-0.64-14.3%$3.53M
2023-03-31$-0.91$-0.85+6.6%$2.34M
2022-12-31$-0.17$-0.78-358.8%

Frequently asked questions

Has NovaBay Pharmaceuticals Inc beaten earnings estimates?
NovaBay Pharmaceuticals Inc has beaten Wall Street EPS estimates in 1 of its last 8 quarterly reports, with an average EPS surprise of -64.9% over the last 3 quarters.
How does NBY stock react to earnings?
NBY stock has moved an average of +0.9% in the trading day following earnings over its last 1 reports, with positive reactions in 100% of those quarters.
What is NovaBay Pharmaceuticals Inc's revenue growth rate?
NovaBay Pharmaceuticals Inc reported year-over-year revenue growth of -78.7% in its most recent quarter, with EPS growing +61.0% year-over-year.